Back to Search
Start Over
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
- Source :
- Case Reports in Oncology, Vol 9, Iss 1, Pp 51-55 (2016)
- Publication Year :
- 2016
- Publisher :
- Karger Publishers, 2016.
-
Abstract
- Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.
Details
- Language :
- English
- ISSN :
- 16626575
- Volume :
- 9
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Case Reports in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.48d9358043204380944d602ab615e5ad
- Document Type :
- article
- Full Text :
- https://doi.org/10.1159/000443662